PALO ALTO, Calif., Aug. 21, 2019 /PRNewswire/ -- Varian (NYSE:
VAR) today announced that Phil
Febbo, MD, chief medical officer (CMO) at Illumina has been
appointed to the Varian Board of Directors, effective August 16, 2019.
"We are proud to have Phil Febbo
join the Varian Board," said R. Andrew
Eckert, chairman of Varian's Board of Directors. "Phil has a
strong background in both clinical and research work, as well as
company strategy. He will be another valuable member of the Varian
Board as the company continues its transformation into the leader
in intelligent cancer care."
"Varian is a leader in addressing the global cancer challenge by
developing innovative solutions that are increasing access to high
quality care," said Febbo. "It is an exciting time to join the
Varian Board, as the company expands beyond its traditional
radiotherapy focus and puts the patient and clinician at the center
of its thinking to deliver intelligent cancer care. I look forward
to joining the Board and being a part of the company's vision of
creating a world without fear of cancer."
Dr. Febbo, 53, has served as CMO at Illumina since 2018 and is
responsible for developing and executing the Company's medical
strategy to drive genomic testing into healthcare practice in order
to improve health outcomes. Prior to joining Illumina, he served as
CMO of Genomic Health for five years where he drove the
company's medical strategy, was accountable for the development of
evidence supporting GHI's proprietary tests, engaged with the payer
community to drive reimbursement, and served as a corporate officer
between 2016 and 2018. Prior to Genomic Health, Dr. Febbo was a
Professor of Medicine and Urology at the University of
California, San
Francisco (UCSF), where his laboratory focused on using
genomics to understand the biology and clinical behavior of
prostate cancer, and his clinical practice focused on genitourinary
oncology. He currently serves on the board of the American College
of Medical Genetics and Genomics Foundation.
Dr. Febbo holds a Bachelor of Arts degree in Biology
from Dartmouth College and an M.D. from UCSF. He completed his
internal medicine residency at the Brigham and Women's Hospital and
his fellowship in oncology at the Dana-Farber Cancer
Institute.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 9,200 employees across 70 countries keep
the patient and our clinical partners at the center of our thinking
as we power new victories in cancer care. Because, for cancer
patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Mark Plungy
Director, Global Public Relations
+1 (650) 424-5630
mark.plungy@varian.com
Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/dr-phil-febbo-named-to-varian-board-of-directors-300905357.html
SOURCE Varian